SCHEMBL4773954

SCHEMBL4773954

NCc1nc2ncccc2[nH]1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NUDT1 P36639 1/20 0.59
CYP2C9 P11712 1/20 0.49
NOS1 P29475 1/20 0.49
NOS2 P35228 1/20 0.49
METAP1 P53582 2/20 0.49
METAP2 P50579 1/20 0.49
DRD4 P21917 1/20 0.47
TP53 P04637 4/20 0.46
PDE5A O76074 3/20 0.45
HPGD P15428 3/20 0.44
AURKA O14965 4/20 0.44
SMN1; SMN2 Q16637 4/20 0.43
NPC1 O15118 3/20 0.43
RAB9A P51151 3/20 0.43
NPSR1 Q6W5P4 1/20 0.43
POLB P06746 1/20 0.43
ALDH1A1 P00352 1/20 0.42
BACE1 P56817 1/20 0.42
HSD17B10 Q99714 1/20 0.42
FGFR1 P11362 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7002580 0.85 NUDT1 (0.58) NUDT1CYP2C9NOS1NOS2METAP1
SCHEMBL4719992 0.83 NUDT1 (0.53) NUDT1CYP2C9NOS1NOS2METAP1
SCHEMBL31587712 0.81 NUDT1 (0.55) NUDT1CYP2C9NOS1NOS2METAP1
SCHEMBL3967813 0.81 NUDT1 (0.55) NUDT1CYP2C9NOS1NOS2METAP1
SCHEMBL4347800 0.81 NUDT1 (0.55) NUDT1CYP2C9NOS1NOS2METAP1
SCHEMBL6216010 0.81 NUDT1 (0.55) NUDT1CYP2C9NOS1NOS2METAP1
SCHEMBL2314765 0.81 DDAH1 (0.55) NUDT1CYP2C9NOS1NOS2METAP1
Hydrochloric Acid SCHEMBL5864683 0.80 NUDT1 (0.53) NUDT1CYP2C9NOS1NOS2METAP1
SCHEMBL3960231 0.79 CYP2C9 (0.57) NUDT1CYP2C9NOS1NOS2METAP1
SCHEMBL9570423 0.79 CYP2C9 (0.53) NUDT1CYP2C9NOS1NOS2METAP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220106327-A1 INHIBITORS OF APOL1 AND METHODS OF USING SAME VERTEX PHARMACEUTICALS INCORPORATED (US) 2022-04-07 US disclosed
WO-2018048930-A1 LYSYL OXIDASE-LIKE 2 INHIBITORS AND USES THEREOF PHARMAKEA, INC. (US) 2018-03-15 WO disclosed
EP-2300485-B1 PYRROLO-[2, 3-C]-PYRIDINE DERIVATIVES AS P38 KINASE INHIBITING AGENTS MERCK SHARP & DOHME (US) 2012-01-18 EP disclosed
US-8017605-B2 P38 kinase inhibiting agents MERCK SHARP & DOHME CORP. (US) 2011-09-13 US disclosed
US-8017605-B2 P38 kinase inhibiting agents MERCK SHARP & DOHME CORP. (US) 2011-09-13 US disclosed
US-20110105430-A1 PYRROLO [2,3-C] PYRIDINE DERIVATIVES AS P38 KINEASE INHIBITING AGENTS SAHOO SOUMYA P 2011-05-05 US disclosed
US-20090325953-A1 P38 KINASE INHIBITING AGENTS MERCK SHARP & DOHME LLC 2009-12-31 US disclosed
US-20090325953-A1 P38 KINASE INHIBITING AGENTS MERCK SHARP & DOHME LLC 2009-12-31 US disclosed
WO-2009152072-A1 PYRROLO [2, 3-C] PYRIDINE DERIVATIVES AS P38 KINASE INHIBITING AGENTS MERCK & CO., INC. (US) 2009-12-17 WO disclosed
EP-1879889-A1 PROCESS FOR MAKING FLUORINATED 4-AZASTEROID DERIVATIVES AND INTERMEDIATE THEREOF Merck & Co., Inc. (US) 2008-01-23 EP disclosed
US-7301026-B2 Process for making fluorinated 4-azasteroid derivatives MERCK & CO., INC (US) 2007-11-27 US disclosed
WO-2006121655-A1 PROCESS FOR MAKING FLUORINATED 4-AZASTEROID DERIVATIVES AND INTERMEDIATE THEREOF MERCK & CO., INC. (US) 2006-11-16 WO disclosed
US-20060252937-A1 Process for making fluorinated 4-azasteroid derivatives MERCK SHARP & DOHME CORP. 2006-11-09 US disclosed
EP-1176959-B1 NOVEL PROLINES AS ANTIMICROBIAL AGENTS MERCK & CO INC (US) 2006-03-08 EP disclosed
US-6579894-B2 Bactericides, fungicides MERCK & CO., INC. 2003-06-17 US disclosed
US-20030013724-A1 Novel prolines as antimicrobial agents HAMMOND MILTON L (US) 2003-01-16 US disclosed
US-6417217-B1 TREATING INFECTIONS WITH HETEROCYCLIC MICROBIOCIDES THIS INVENTION RELATES TO THE FIELD OF TRANSFER RIBONUCLEIC ACID (TRNA) SYNTHETASE INHIBITORS, THEIR PREPARATION AND THEIR USE AS ANTIMICROBIAL ADMINISTERING TO THE SUBJECT A MERCK & CO., INC. 2002-07-09 US disclosed
US-6333344-B1 ENZYME INHIBITORS AND BACTERICIDES MERCK & CO. 2001-12-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030013724-A1 Novel prolines as antimicrobial agents AARS1, EPRS1, TRMT1 NUDT1 266/4885CYP2C9 1873/4885NOS1 2168/4885
US-20220106327-A1 INHIBITORS OF APOL1 AND METHODS OF USING SAME APOL1, PNLIP, APOB NUDT1 1139/4885CYP2C9 4414/4885NOS1 3294/4885
US-20090325953-A1 P38 KINASE INHIBITING AGENTS MAPK1, MAPK8, MAPKAPK2 NUDT1 1078/4885CYP2C9 1305/4885NOS1 95/4885
US-20060252937-A1 Process for making fluorinated 4-azasteroid derivatives FSHR, CYP17A1, CYP19A1 NUDT1 1804/4885CYP2C9 742/4885NOS1 904/4885
US-20110105430-A1 PYRROLO [2,3-C] PYRIDINE DERIVATIVES AS P38 KINEASE INHIBITING AGENTS MAPK1, MAP3K8, MAPK8 NUDT1 638/4885CYP2C9 1142/4885NOS1 592/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.